12.07.2015 Views

Evaluación cuantitativa del riesgo de cáncer de mama

Evaluación cuantitativa del riesgo de cáncer de mama

Evaluación cuantitativa del riesgo de cáncer de mama

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

[Rev. Med. Clin. Con<strong>de</strong>s - 2006; 17(4): 149 - 63]162tomy. J Clin Oncol 18:2406-12, 2000.72> Fowble B, Hanlon A, Freedman G,et al: Second cancers after conservativesurgery and radiation for stages I-IIbreast cancer: i<strong>de</strong>ntifying a subset of womenat increased risk. Int J Radiat OncolBiol Phys 51:679-90, 2001.73> La<strong>de</strong>n F, Hunter DJ: Environmentalrisk factors and female breast cancer. AnnuRev Public Health 19:101-23, 1998.74> Terry PD, Rohan TE: Cigarette smokingand the risk of breast cancer in women:a review of the literature. CancerEpi<strong>de</strong>miol Biomarkers Prev 11:953-71,2002.75> Ambrosone C: Impact of genesis onthe relation-ship between smoking andbreast cancer risk. J Womens Cancer3:17-22, 2001.76> Slattery ML, Kerber RA: A comprehensiveevaluation of family history andbreast cancer risk. The Utah PopulationDatabase. Jama 270:1563-8, 1993.77> Claus EB, Risch NJ, ThompsonWD: Age at onset as an indicator of familialrisk of breast cancer. Am J Epi<strong>de</strong>miol131:961-72, 1990.78> Claus EB, Schildkraut JM, ThompsonWD, et al: The genetic attributablerisk of breast and ovarian cancer. Cancer77:2318-24, 1996.79> Struewing JP, Hartge P, Wachol<strong>de</strong>rS, et al: The risk of cancer associatedwith specific mutations of BRCA1 andBRCA2 among Ashkenazi Jews. N EnglJ Med 336:1401-8, 1997.80> Ford D, Easton DF, Peto J: Estimatesof the gene frequency of BRCA1 and itscontribution to breast and ovarian cancerinci<strong>de</strong>nce. Am J Hum Genet 57:1457-62,1995.81> Peto J, Collins N, Barfoot R, et al:Prevalence of BRCA1 and BRCA2 genemutations in patients with early-onsetbreast cancer. J Natl Cancer Inst 91:943-9, 1999.82> Satagopan JM, Offit K, Foulkes W,et al: The lifetime risks of breast cancerin Ashkenazi Jewish carriers of BRCA1and BRCA2 mutations. Cancer Epi<strong>de</strong>miolBiomarkers Prev 10:467-73, 2001.83> Hall JM, Lee MK, Newman B, etal: Linkage of early-onset familial breastcancer to chromosome 17q21. Science250:1684-9, 1990.84> Newman B, Mu H, Butler LM, et al:Frequency of breast cancer attributableto BRCA1 in a population-based seriesof American women. Jama 279:915-21,1998.85> Whittemore AS, Gong G, Itnyre J:Prevalence and contribution of BRCA1mutations in breast cancer and ovariancancer: results from three U.S. population-basedcase-control studies of ovariancancer. Am J Hum Genet 60:496-504, 1997.86> Couch FJ, DeShano ML, BlackwoodMA, et al: BRCA1 mutations in womenattending clinics that evaluate the risk ofbreast cancer. N Engl J Med 336:1409-15, 1997.87> Shattuck-Ei<strong>de</strong>ns D, Oliphant A, Mc-Clure M, et al: BRCA1 sequence analysisin women at high risk for susceptibilitymutations. Risk factor analysis andimplications for genetic testing. Jama278:1242-50, 1997.88> Wooster R, Neuhausen SL, MangionJ, et al: Localization of a breast cancersusceptibility gene, BRCA2, to chromosome13q12-13. Science 265:2088-90,1994.89> Ford D, Easton DF, Stratton M, etal: Genetic heterogeneity and penetranceanalysis of the BRCA1 and BRCA2 genesin breast cancer families. The BreastCancer Linkage Consortium. Am J HumGenet 62:676-89, 1998.90> Easton DF, Ford D, Bishop DT:Breast and ovarian cancer inci<strong>de</strong>nce inBRCA1-mutation carriers. Breast CancerLinkage Consortium. Am J Hum Genet56:265-71, 1995.91> Brose MS, Rebbeck TR, CalzoneKA, et al: Cancer risk estimates forBRCA1 mutation carriers i<strong>de</strong>ntified in arisk evaluation program. J Natl CancerInst 94:1365-72, 2002.92> Marcus JN, Watson P, Page DL, etal: Hereditary breast cancer: pathobiology,prognosis, and BRCA1 and BRCA2gene linkage. Cancer 77:697-709, 199693> Cancer risks in BRCA2 mutation carriers.TheBreast Cancer Linkage Consortium.J Natl Cancer Inst 91:1310-6, 1999.94> Ford D, Easton DF, Bishop DT, etal: Risks of cancer in BRCA1-mutationcarriers. Breast Cancer Linkage Consortium.Lancet 343:692-5, 1994.95> Statement of the American Societyof Clinical Oncology: genetic testing forcancer susceptibility, Adopted on February20, 1996. J Clin Oncol 14:1730-6;discussion 1737-40, 1996.96> Krieger N, Hiatt RA: Risk of breastcancer after benign breast diseases. Variationby histologic type, <strong>de</strong>gree of atypia,age at biopsy, and length of followup.Am J Epi<strong>de</strong>miol 135:619-31, 1992.97> Mommers EC, Page DL, DupontWD, et al: Prognostic value of morphometryin patients with normal breasttissue or usual ductal hyperplasia of thebreast. Int J Cancer 95:282-5, 2001.98> Bodian CA, Perzin KH, Lattes R,et al: Prognostic significance of benignproliferative breast disease. Cancer71:3896-907, 1993.99> Page DL, Dupont WD, Rogers LW,et al: Atypical hyperplastic lesions of thefemale breast. A long-term follow-upstudy. Cancer 55:2698-708, 1985.100> Tavassoli FA, Norris HJ: A comparisonof the results of long-term followupfor atypical intraductal hyperplasiaand intraductal hyperplasia of the breast.Cancer 65:518-29, 1990.101> Moskowitz M, Gartsi<strong>de</strong> P, WirmanJA, et al: Proliferative disor<strong>de</strong>rs of thebreast as risk factors for breast cancerin a self-selected screened population:pathologic markers. Radiology 134:289-91, 1980.102> Marshall LM, Hunter DJ, ConnollyJL, et al: Risk of breast cancer associatedwith atypical hyperplasia of lobular andductal types. Cancer Epi<strong>de</strong>miol BiomarkersPrev 6:297-301, 1997.103> Dupont WD, Page DL: Relativerisk of breast cancer varies with timesince diagnosis of atypical hyperplasia.Hum Pathol 20:723-5, 1989.ARCHIVO.indd 162 26/11/06 05:24:39

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!